MG
MCID: MYS003
MIFTS: 68

Myasthenia Gravis (MG)

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Myasthenia Gravis

MalaCards integrated aliases for Myasthenia Gravis:

Name: Myasthenia Gravis 57 12 73 20 43 53 58 36 29 54 42 44 15 37 17 70 32
Mg 57 43
Autoimmune Myasthenia Gravis 58
Acquired Myasthenia 58

Characteristics:

Orphanet epidemiological data:

58
myasthenia gravis
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe),1-9/100000 (Worldwide),1-9/1000000 (United States),1-5/10000 (Canada),1-9/100000 (Spain),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/100000 (Serbia),1-5/10000 (United States),1-5/10000 (Serbia),1-9/100000 (Italy),1-5/10000 (Austria),1-9/100000 (Australia),1-5/10000 (Italy),1-9/100000 (Taiwan, Province of China),1-5/10000 (Australia),1-9/1000000 (Greece),1-5/10000 (Taiwan, Province of China),1-9/1000000 (Croatia),1-9/100000 (Estonia),1-9/100000 (Greece),1-9/100000 (Croatia),1-9/100000 (Egypt),1-9/1000000 (Worldwide); Age of onset: All ages; Age of death: normal life expectancy;

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
usually sporadic
1 to 4 % of cases are familial without a simple mendelian pattern
familial predisposition may be due to autoimmunity in general.


HPO:

31
myasthenia gravis:
Inheritance multifactorial inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases


Summaries for Myasthenia Gravis

MedlinePlus Genetics : 43 Myasthenia gravis is a disorder that causes weakness of the skeletal muscles, which are muscles that the body uses for movement. The weakness most often starts in the muscles around the eyes, causing drooping of the eyelids (ptosis) and difficulty coordinating eye movements, which results in blurred or double vision. In a form of the disorder called ocular myasthenia, the weakness remains confined to the eye muscles. In most people with myasthenia gravis, however, additional muscles in the face and neck are affected. Affected individuals may have unusual facial expressions, difficulty holding up the head, speech impairment (dysarthria), and chewing and swallowing problems (dysphagia) that may lead to choking, gagging, or drooling.Other muscles in the body are also affected in some people with myasthenia gravis. The muscles of the arms and legs may be involved, causing affected individuals to have changes in their gait or trouble with lifting objects, rising from a seated position, or climbing stairs. The muscle weakness tends to fluctuate over time; it typically worsens with activity and improves with rest.Weakness of the muscles in the chest wall and the muscle that separates the abdomen from the chest cavity (the diaphragm) can cause breathing problems in some people with myasthenia gravis. About 10 percent of people with this disorder experience a potentially life-threatening complication in which these respiratory muscles weaken to the point that breathing is dangerously impaired, and the affected individual requires ventilation assistance. This respiratory failure, called a myasthenic crisis, may be triggered by stresses such as infections or reactions to medications.People can develop myasthenia gravis at any age. For reasons that are unknown, it is most commonly diagnosed in women younger than age 40 and men older than age 60. It is uncommon in children, but some infants born to women with myasthenia gravis show signs and symptoms of the disorder for the first few days or weeks of life. This temporary occurrence of symptoms is called transient neonatal myasthenia gravis.

MalaCards based summary : Myasthenia Gravis, also known as mg, is related to neonatal myasthenia gravis and thymoma, and has symptoms including ptosis, diplopia and dysarthria. An important gene associated with Myasthenia Gravis is AKAP12 (A-Kinase Anchoring Protein 12), and among its related pathways/superpathways are Allograft rejection and Immune response NFAT in immune response. The drugs Neurotransmitter Agents and Cholinergic Agents have been mentioned in the context of this disorder. Affiliated tissues include thymus, eye and t cells, and related phenotypes are ptosis and diplopia

Disease Ontology : 12 An autoimmune disease of the nervous system that has material basis in antibodies to acetylcholine receptors at the neuromuscular junction, has symptom ptosis, has symptom diplopia, has symptom dysphagia, has symptom dysarthria, has symptom muscle weakness and has symptom shortness of breath.

GARD : 20 Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. Common symptoms include weakness of the muscles that control the eye and eyelid, facial expressions, chewing, talking, and swallowing. Weakness tends to increase during periods of activity and improve after periods of rest. The condition results from a defect in the transmission of nerve impulses to muscles, which is due to the presence of antibodies against acetylcholine. The exact reason this occurs is not known. Some cases have been linked to tumors in the thymus gland. Researchers believe that variations in certain genes may increase a person's risk to develop MG, but other factors likely also play a role. There is no cure for MG at this time, but treatment can significantly improve muscle weakness. Some cases may go into remission temporarily, and muscle weakness may disappear so that medications can be discontinued.

MedlinePlus : 42 Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke

NINDS : 53 Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal muscles of the body, which are responsble for breathing and moving parts of the body, including the arms and legs. In myasthenia gravis, the immune system--which normally protects the body from foreign organisms--mistakenly attacks itself.   Symptoms vary in type and intensity, and may include: • muscle weakness in the arms, hands, fingers, legs and neck • weakness of the eye muscles • drooping eyelid • difficulty swallowing • shortness of breath • impaired speaking Myasthenia gravis is caused by an error in the transmission of nerve impulses to muscles. Antibodies (immune proteins produced by the body's immune system) block the normal activity of the neurotransmitter acetylcholine, which prevents muscles from contracting. The thymus gland also may give incorrect instructions to immune cells and cause the immune system to attack its own cells and tissues. .

KEGG : 36 Myasthenia gravis (MG) is an autoimmune disorder characterized by a defective transmission of nerve impulses to muscles leading to muscle weakness and fatigability. Some, but not all, muscles are affected and not necessarily symmetrically. Increased weakness with continued muscle activity represents a diagnostic clue for MG, but these clinical features can vary. MG is B-cell mediated, and is associated with antibodies directed against the acetylcholine receptor (AChR), muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic membrane at the neuromuscular junction. Patients should be classified into subgroups to help with therapeutic decisions and prognosis. Subgroups based on serum antibodies and clinical features include early-onset, late-onset, thymoma, MUSK, LRP4, antibody-negative, and ocular forms of myasthenia gravis. Agrin-associated MG might emerge as a new entity. The prognosis is good with optimum symptomatic, immunosuppressive, and supportive treatment. The evolution of MG is unpredictable, but it is generally characterized by the occurrence of relapses, sometimes subsequent to remissions and a worsening trend. For 85% of MG patients, the maximum severity is reached within less than 3 years.

Wikipedia : 73 Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal... more...

More information from OMIM: 254200

Related Diseases for Myasthenia Gravis

Diseases in the Myasthenia Gravis family:

Juvenile Myasthenia Gravis Adult-Onset Myasthenia Gravis

Diseases related to Myasthenia Gravis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1164)
# Related Disease Score Top Affiliating Genes
1 neonatal myasthenia gravis 33.0 MUSK CHRNG AGRN
2 thymoma 32.6 TTN RYR1 IL2 CTLA4 AIRE
3 neuromyelitis optica 32.2 TNFSF13B MBP IL4
4 multiple pterygium syndrome, escobar variant 32.1 RYR1 RAPSN CHRNG CHRNE CHRNA1
5 thymus cancer 32.1 TTN MUSK IL2 CTLA4 AIRE AGRN
6 ptosis 32.1 RYR1 RAPSN MUSK CHRNG CHRNE CHRNA1
7 congenital myasthenic syndrome 31.9 TTN TNF RYR1 RAPSN MUSK IL2
8 lambert-eaton myasthenic syndrome 31.8 TTN TNF MUSK IL10
9 respiratory failure 31.7 TTN TNF RYR1 MUSK IL10 ACHE
10 lupus erythematosus 31.7 TNF IL10 IFNG CTLA4
11 myositis 31.6 TTN TNF RYR1 IL2 IFNG
12 neuromuscular disease 31.6 TTN TMPO RYR1 RAPSN MUSK CHRNG
13 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.5 TNFSF13B IL10 IFNG CTLA4 AIRE
14 pemphigus 31.4 TNFSF13B TNF IL4 IL10
15 neuromuscular junction disease 31.3 RAPSN MUSK CHRNG CHRNE CHRNA1 AGRN
16 myopathy 31.3 TTN TNFSF13B RYR1 RAPSN IL4 IFNG
17 myelitis 31.3 TNF MBP IL10
18 graft-versus-host disease 31.3 TNF IL2 IL10 IFNG
19 myocarditis 31.2 TTN TNF IL4 IL2 IL10 IFNG
20 autoimmune disease 31.2 TNFSF13B TNF MUSK MBP IL4 IL2
21 graves' disease 31.2 IL4 IFNG CTLA4 AIRE
22 chronic graft versus host disease 31.2 TNFSF13B IL10 IFNG
23 chronic inflammatory demyelinating polyradiculoneuropathy 31.2 MBP IL10 IFNG
24 transverse myelitis 31.1 TNF MBP IL10
25 purpura 31.1 TNFSF13B TNF IL4 IL10 IFNG
26 optic neuritis 31.1 TNF MBP IL10
27 thyroiditis 31.0 TNF IL4 IL2 IL10 IFNG CTLA4
28 severe acute respiratory syndrome 31.0 TNF IL10 IFNG
29 systemic scleroderma 31.0 TNF IL4 IL10 IFNG
30 cholangitis 31.0 TNF IL2 IL10 CTLA4
31 ulcerative colitis 31.0 TNF IL4 IL2 IL10 IFNG
32 vitiligo-associated multiple autoimmune disease susceptibility 1 30.9 TNF IL2 CTLA4 AIRE
33 neuritis 30.9 TNF MBP IL4 IL10 IFNG CHRNG
34 hashimoto thyroiditis 30.9 IL4 IL10 IFNG CTLA4 AIRE
35 lichen planus 30.9 TNF IL4 IL2 IL10 IFNG
36 exanthem 30.9 TNF IL2 IL10 IFNG CTLA4
37 meningitis 30.9 TNF IL4 IL2 IL10 IFNG
38 distal arthrogryposis 30.9 TTN RYR1 RAPSN CHRNG
39 severe combined immunodeficiency 30.8 IL4 IL2 IL10 IFNG
40 polyradiculoneuropathy 30.8 MBP IL10 IFNG
41 pemphigoid 30.8 TNF IL4 IFNG
42 spondylitis 30.8 TNF IL10 IFNG
43 alopecia 30.8 TNF IL4 IL2 IFNG CTLA4 AIRE
44 aseptic meningitis 30.8 TNF IL10 IFNG
45 sclerosing cholangitis 30.8 TNF IL2 IL10 CTLA4
46 lymphadenitis 30.8 TNF IL10 IFNG
47 pneumonia 30.8 TNF IL4 IL10 IFNG
48 aplastic anemia 30.8 TNF IL4 IL2 IL10 IFNG CTLA4
49 lymphopenia 30.8 IL4 IL2 IL10 IFNG CTLA4
50 myasthenic syndrome, congenital, 4c, associated with acetylcholine receptor deficiency 30.7 RAPSN MUSK CHRNE

Graphical network of the top 20 diseases related to Myasthenia Gravis:



Diseases related to Myasthenia Gravis

Symptoms & Phenotypes for Myasthenia Gravis

Human phenotypes related to Myasthenia Gravis:

58 31 (show all 40)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ptosis 58 31 frequent (33%) Frequent (79-30%) HP:0000508
2 diplopia 58 31 frequent (33%) Frequent (79-30%) HP:0000651
3 dysarthria 58 31 frequent (33%) Frequent (79-30%) HP:0001260
4 dysphagia 58 31 frequent (33%) Frequent (79-30%) HP:0002015
5 dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002094
6 ophthalmoparesis 58 31 frequent (33%) Frequent (79-30%) HP:0000597
7 myositis 58 31 frequent (33%) Frequent (79-30%) HP:0100614
8 bulbar palsy 58 31 frequent (33%) Frequent (79-30%) HP:0001283
9 abnormality of the thymus 58 31 frequent (33%) Frequent (79-30%) HP:0000777
10 single fiber emg abnormality 58 31 frequent (33%) Frequent (79-30%) HP:0030006
11 acetylcholine receptor antibody positivity 58 31 frequent (33%) Frequent (79-30%) HP:0030208
12 muscle specific kinase antibody positivity 58 31 frequent (33%) Frequent (79-30%) HP:0030210
13 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
14 hashimoto thyroiditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000872
15 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
16 hyperthyroidism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000836
17 hyperacusis 58 31 occasional (7.5%) Occasional (29-5%) HP:0010780
18 primary adrenal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0008207
19 raynaud phenomenon 58 31 occasional (7.5%) Occasional (29-5%) HP:0030880
20 glycosuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0003076
21 rheumatoid arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001370
22 systemic lupus erythematosus 58 31 occasional (7.5%) Occasional (29-5%) HP:0002725
23 acrocyanosis 58 31 very rare (1%) Very rare (<4-1%) HP:0001063
24 hepatitis 58 31 very rare (1%) Very rare (<4-1%) HP:0012115
25 hemolytic anemia 58 31 very rare (1%) Very rare (<4-1%) HP:0001878
26 psychosis 58 31 very rare (1%) Very rare (<4-1%) HP:0000709
27 pure red cell aplasia 58 31 very rare (1%) Very rare (<4-1%) HP:0012410
28 seizure 31 very rare (1%) HP:0001250
29 seizures 58 Very rare (<4-1%)
30 facial palsy 31 HP:0010628
31 muscle weakness 58 Very frequent (99-80%)
32 autoimmunity 31 HP:0002960
33 abnormality of the immune system 31 HP:0002715
34 nasal speech 31 HP:0001611
35 abnormality of the endocrine system 31 HP:0000818
36 limb muscle weakness 31 HP:0003690
37 proximal muscle weakness 31 HP:0003701
38 impaired mastication 31 HP:0005216
39 fatigable weakness 31 HP:0003473
40 thymoma 31 HP:0100522

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
H E E N T:
ptosis
diplopia
dysarthria
facial muscle weakness
difficulty chewing

Immunology:
autoimmunity
thymoma
antibodies to acetylcholine receptor (achr)
association with gm type

Muscle:
proximal limb muscle weakness.

Pulmonary:
ventilatory insufficiency

G I:
dysphagia

Voice:
nasal speech

Endocrine:
thyrotoxicosis

Misc:
childhood or adolescent onset
static or only slowly progressive

Clinical features from OMIM®:

254200 (Updated 05-Apr-2021)

Symptoms:

12
  • ptosis
  • diplopia
  • dysarthria
  • dysphagia
  • muscle weakness
  • shortness of breath

UMLS symptoms related to Myasthenia Gravis:


seizures; tremor; muscle weakness; back pain; headache; syncope; pain; chronic pain; sciatica; vertigo/dizziness; sleeplessness; facial paresis

GenomeRNAi Phenotypes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-107 9.96 ACHE
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-126 9.96 MUSK
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-128 9.96 IL10
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.96 IL10
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-161 9.96 AIRE
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.96 IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.96 IL10
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-194 9.96 TNFSF13B
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.96 AIRE
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.96 TNFSF13B
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 9.96 IL10
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-32 9.96 MUSK
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.96 IL10
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-39 9.96 TNFSF13B
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.96 AIRE
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.96 ACHE
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 9.96 MUSK
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-8 9.96 TNFSF13B
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-80 9.96 IL10
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 9.96 AIRE
21 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.6 TMPO
22 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.6 RAPSN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.6 CHRNA1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.6 TMPO
25 Increased shRNA abundance (Z-score > 2) GR00366-A-141 9.6 TMPO
26 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.6 TMPO
27 Increased shRNA abundance (Z-score > 2) GR00366-A-155 9.6 CHRNA1 RAPSN
28 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.6 TMPO
29 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.6 CHRNA1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.6 TMPO
31 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.6 RAPSN
32 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.6 CHRNA1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.6 CHRNA1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.6 CHRNA1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.6 CHRNA1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.6 CHRNA1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.6 CHRNA1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.6 RAPSN

MGI Mouse Phenotypes related to Myasthenia Gravis:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.42 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
2 growth/size/body region MP:0005378 10.37 ACHE AGRN AIRE CHRNE CHRNG IFNG
3 homeostasis/metabolism MP:0005376 10.37 ACHE AGRN AIRE CHRNG CTLA4 IFNG
4 hematopoietic system MP:0005397 10.36 ACHE AIRE AKAP12 CTLA4 IFNG IL10
5 mortality/aging MP:0010768 10.36 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
6 immune system MP:0005387 10.29 AIRE AKAP12 CTLA4 IFNG IL10 IL2
7 digestive/alimentary MP:0005381 10.19 AIRE CTLA4 IFNG IL10 IL2 IL4
8 nervous system MP:0003631 10.17 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
9 muscle MP:0005369 10.15 ACHE AGRN AKAP12 CHRNE CHRNG IFNG
10 integument MP:0010771 10.11 CHRNG CTLA4 IFNG IL10 IL4 MUSK
11 liver/biliary system MP:0005370 10.03 AIRE AKAP12 CTLA4 IFNG IL10 IL2
12 no phenotypic analysis MP:0003012 9.86 ACHE AIRE CHRNE IFNG IL10 IL2
13 respiratory system MP:0005388 9.83 ACHE AGRN AIRE AKAP12 CHRNE CHRNG
14 normal MP:0002873 9.81 AGRN AIRE AKAP12 CTLA4 IFNG IL10
15 vision/eye MP:0005391 9.28 ACHE AIRE IFNG IL10 IL2 IL4

Drugs & Therapeutics for Myasthenia Gravis

Drugs for Myasthenia Gravis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Neurotransmitter Agents Phase 4
2 Cholinergic Agents Phase 4
3 Cholinesterase Inhibitors Phase 4
4 Bromides Phase 4
5
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643 439492
6
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
7
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 3 14838-15-4 26934
8
tannic acid Approved Phase 3 1401-55-4
9
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
10
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
11
Amifampridine Approved, Investigational Phase 3 54-96-6 5918
12
rituximab Approved Phase 3 174722-31-7 10201696
13
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
14
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
15
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
16
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
17
Rozanolixizumab Investigational Phase 3 1584645-37-3
18 Immunoglobulins, Intravenous Phase 3
19 gamma-Globulins Phase 3
20 Rho(D) Immune Globulin Phase 3
21 Calcineurin Inhibitors Phase 3
22 Vaccines Phase 3
23 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
24 Adrenergic beta-Agonists Phase 2, Phase 3
25 Respiratory System Agents Phase 2, Phase 3
26 Anti-Asthmatic Agents Phase 2, Phase 3
27 Albuterol Phase 2, Phase 3
28 Adrenergic Agents Phase 2, Phase 3
29 Tocolytic Agents Phase 2, Phase 3
30 Adrenergic Agonists Phase 2, Phase 3
31 Bronchodilator Agents Phase 2, Phase 3
32 Potassium Channel Blockers Phase 3
33 Antineoplastic Agents, Immunological Phase 3
34 Pharmaceutical Solutions Phase 3
35 Complement System Proteins Phase 3
36 Immunologic Factors Phase 3
37 Immunosuppressive Agents Phase 3
38 glucocorticoids Phase 3
39 Hormone Antagonists Phase 3
40 Hormones Phase 3
41 Antineoplastic Agents, Hormonal Phase 3
42 Anti-Inflammatory Agents Phase 3
43 Pyridostigmine Bromide Phase 3 101-26-8
44
belimumab Approved Phase 2 356547-88-1 5957 10451420
45
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
46
Carmustine Approved, Investigational Phase 2 154-93-8 2578
47
Etoposide Approved Phase 2 33419-42-0 36462
48
Melphalan Approved Phase 2 148-82-3 4053 460612
49
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
50
Ondansetron Approved Phase 2 99614-02-5 4595

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 A Randomized Trial of Plasma Exchange vs. IVIG in the Treatment of Myasthenia Gravis Completed NCT01179893 Phase 4
2 Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study Completed NCT00987116 Phase 4 Prednisone - Azathioprine
3 Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis Recruiting NCT03510546 Phase 4 Pyridostigmine;Placebo oral capsule
4 A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis Exacerbation Unknown status NCT02774239 Phase 3 Human normal immunoglobulin G (IgG)
5 IVIG Treatment Compared to Placebo in Patients With Myasthenia Gravis: A Randomized Clinical Trial Completed NCT00306033 Phase 3 Intravenous ImmuneGlobulin
6 A Trial of Mycophenolate Mofetil in Myasthenia Gravis Completed NCT00285350 Phase 3 mycophenolate mofetil
7 A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone Completed NCT00294658 Phase 3 prednisone alone
8 A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients Completed NCT03304054 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
9 A Randomized, Double-Blind Study to Evaluate the Safety of Continued Treatment With CellCept in Patients With Well-Controlled Myasthenia Gravis Receiving a Stable Dose of Prednisone Completed NCT00408213 Phase 3 mycophenolate mofetil [CellCept];Placebo
10 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness Completed NCT03669588 Phase 3
11 FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients Completed NCT00309088 Phase 3 tacrolimus;placebo
12 A Phase III, Open-label Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) Completed NCT02301624 Phase 3 Placebo
13 A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy Completed NCT01325571 Phase 3 Tacrolimus capsule;Placebo
14 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) Completed NCT01997229 Phase 3 Placebo
15 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, 36-Week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symptom Control With Reduced Corticosteroid in Subjects With Myasthenia Gravis Completed NCT00683969 Phase 3 mycophenolate mofetil (CellCept);placebo
16 A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations Completed NCT02413580 Phase 3
17 A Randomized, Controlled Clinical Study of GB-0998 for Treatment of Generalized Myasthenia Gravis Completed NCT00515450 Phase 3
18 FK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG Patients Completed NCT00309101 Phase 3 tacrolimus
19 The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Recruiting NCT01727193 Phase 3 Azathioprine;Leflunomide
20 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Recruiting NCT03971422 Phase 3 Rozanolixizumab
21 An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients With Refractory Generalized Myasthenia Gravis Recruiting NCT03759366 Phase 3 Eculizumab
22 Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis Recruiting NCT03914638 Phase 2, Phase 3 Salbutamol 4Mg Tablet;Placebo oral capsule
23 A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC With Multiple Intravenous Infusions of Efgartigimod in Patients With Generalized Myasthenia Gravis Recruiting NCT04735432 Phase 3
24 A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis Recruiting NCT04115293 Phase 3 zilucoplan (RA101495);Placebo
25 A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis Recruiting NCT04225871 Phase 3 zilucoplan (RA101495)
26 A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis Recruiting NCT04524273 Phase 3 inebilizumab;IV Placebo
27 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis Active, not recruiting NCT03920293 Phase 3 Placebo
28 Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis Active, not recruiting NCT03579966 Phase 3 Amifampridine Phosphate
29 A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG) Active, not recruiting NCT02950155 Phase 3 Rituximab;Sodium Chloride solution
30 A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness Active, not recruiting NCT03770403 Phase 3
31 An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis Enrolling by invitation NCT04650854 Phase 3 Rozanolixizumab
32 A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Enrolling by invitation NCT04124965 Phase 3 Rozanolixizumab
33 A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis Not yet recruiting NCT04818671 Phase 3
34 Efficacy of Prednisone In the Treatment of Ocular Myasthenia: The EPITOME' Study Terminated NCT00995722 Phase 3 Prednisone;Placebo
35 A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis. Withdrawn NCT03165435 Phase 2, Phase 3
36 Phase II Trial of Methotrexate in Myasthenia Gravis Completed NCT00814138 Phase 2 Methotrexate
37 B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis Completed NCT02110706 Phase 2 Rituximab;Placebo
38 A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis Completed NCT03052751 Phase 2 UCB7665
39 A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients Completed NCT03863080 Phase 2 RVT-1401;Placebo
40 A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis Completed NCT02473952 Phase 2 IGIV-C;Placebo
41 A Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Completed NCT02965573 Phase 2 Placebo
42 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis Completed NCT02473965 Phase 2 IGIV-C;Placebo
43 A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects With Generalized Myasthenia Gravis (MG) Completed NCT01480596 Phase 2
44 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis Completed NCT03772587 Phase 2 M281
45 Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis. Completed NCT00619671 Phase 1, Phase 2 Rituximab (Rituxan)
46 A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis Completed NCT02609022 Phase 1, Phase 2
47 FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
48 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis Completed NCT02565576 Phase 2 Placebo;CFZ533
49 Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis Completed NCT02100969 Phase 2 HIZENTRA ®
50 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis Completed NCT03315130 Phase 2 zilucoplan (RA101495);Placebo

Search NIH Clinical Center for Myasthenia Gravis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cyclophosphamide
Cyclosporine
Neostigmine
Neostigmine bromide
Neostigmine Methylsulfate
Pyridostigmine
Pyridostigmine Bromide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myasthenia Gravis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myasthenia Gravis:
Hematopoietic stem cells for refractory myasthenia gravis
Embryonic/Adult Cultured Cells Related to Myasthenia Gravis:
Peripheral blood-derived hematopoietic stem cells

Cochrane evidence based reviews: myasthenia gravis

Genetic Tests for Myasthenia Gravis

Genetic tests related to Myasthenia Gravis:

# Genetic test Affiliating Genes
1 Myasthenia Gravis 29

Anatomical Context for Myasthenia Gravis

MalaCards organs/tissues related to Myasthenia Gravis:

40
Thymus, Eye, T Cells, Skeletal Muscle, Thyroid, B Cells, Lung

Publications for Myasthenia Gravis

Articles related to Myasthenia Gravis:

(show top 50) (show all 14499)
# Title Authors PMID Year
1
An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. 57 61
17687331 2007
2
Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. 61 57
15843529 2005
3
Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. 57 61
12417565 2002
4
Myasthenia gravis in a woman with congenital AChR deficiency due to epsilon-subunit mutations. 61 57
12034803 2002
5
The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. 57 61
10711889 2000
6
Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. 57 61
10606626 1999
7
Immunogenetic heterogeneity and associated autoimmune disorders in myasthenia gravis: a population-based survey in the province of Ferrara, northern Italy. 57 61
7887131 1994
8
Familial autoimmune myasthenia gravis. 61 57
7908425 1994
9
Familial autoimmune myasthenia gravis with different pathogenetic antibodies. 57 61
3225607 1988
10
Myasthenia gravis in monozygotic twins. Clinical follow-up nine years after thymectomy. 61 57
6541031 1984
11
Heterozygous C2-deficiency and myasthenia gravis. 61 57
7191069 1980
12
Gm allotypes in myasthenia gravis. 57 61
6103092 1980
13
A genetic study of infantile and juvenile myasthenia gravis. 57 61
5026010 1972
14
Familial myasthenia gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families. 61 57
5146412 1971
15
Genetic study of sample of 70 patients with myasthenia gravis. 61 57
4976972 1968
16
Familial myasthenia gravis. 57 61
6036434 1967
17
Myasthenia gravis occurring in families. 57 61
5948009 1966
18
MYASTHENIA GRAVIS IN TWO SIBLINGS. 61 57
14237778 1965
19
Unusual familial occurrence of myasthenia gravis. 61 57
13823698 1960
20
Efficacy and safety of Buzhong Yiqi decoction combined with western medicine in the treatment of myasthenia gravis: A protocol for systematic review and meta-analysis. 61 42
33725947 2021
21
Impact of COVID-19 pandemic and lockdown in a cohort of myasthenia gravis patients in India. 42 61
33460984 2021
22
Electrophysiological investigation for autonomic dysfunction in patients with myasthenia gravis: A prospective study. 42 61
33497057 2021
23
Clinical syndromes of myasthenia in infancy and childhood. A review. 57
341864 1978
24
Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications. 61 54
20138518 2010
25
The use of sugammadex in a patient with myasthenia gravis. 61 54
20105151 2010
26
Structure-activity relationship of quaternary acetylcholinesterase inhibitors - outlook for early myasthenia gravis treatment. 54 61
20345342 2010
27
A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis. 61 54
19675582 2010
28
[Mediation of cellular immune response by TP5 in pathogenesis of myasthenia gravis]. 54 61
20193562 2009
29
Myasthenia gravis patients with anti-MuSK antibodies. 61 54
20102061 2009
30
The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. 61 54
19693092 2009
31
Methylacridinium and its cholinergic properties. 54 61
19565307 2009
32
[Effects of acetylcholinesterase inhibitors on patients with MuSK antibody positive myasthenia gravis]. 61 54
19999149 2009
33
The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. 61 54
19745065 2009
34
Immunocapture and identification of cell membrane protein antigenic targets of serum autoantibodies. 61 54
19332416 2009
35
Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. 61 54
19587811 2009
36
Acetylcholinesterase inhibitors in MG: to be or not to be? 61 54
19260048 2009
37
Autoimmune disorders of the neuromuscular junction. 61 54
19428298 2009
38
Interleukin-10 promoter polymorphisms in myasthenia gravis. 61 54
19299022 2009
39
Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. 54 61
19187062 2009
40
Muscle-specific receptor tyrosine kinase antibody-positive and seronegative myasthenia gravis. 54 61
19349708 2009
41
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. 61 54
18728167 2008
42
Hypothetical review: thymic aberrations and type-I interferons; attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. 54 61
18727623 2008
43
A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. 61 54
18852352 2008
44
Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation. 61 54
18684515 2008
45
Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis. 61 54
18595775 2008
46
Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor. 61 54
18657424 2008
47
Serum BAFF expression in patients with myasthenia gravis. 61 54
18586330 2008
48
Muscle-specific kinase (MuSK) antibody-associated myasthenia gravis after bone marrow transplantation. 54 61
18537145 2008
49
[Thymopentin 5 in treatment of relapse after extended thymectomy: a randomized comparative clinical trial of 135 patients with myasthenia gravis]. 54 61
19087694 2008
50
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. 54 61
18515870 2008

Variations for Myasthenia Gravis

Expression for Myasthenia Gravis

Search GEO for disease gene expression data for Myasthenia Gravis.

Pathways for Myasthenia Gravis

Pathways related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.78 TNFSF13B TNF IL4 IL2 IL10 IFNG
2
Show member pathways
12.59 TNF IL4 IL2 IL10 IFNG
3
Show member pathways
12.56 TNF IL4 IL2 IL10 IFNG CTLA4
4
Show member pathways
12.55 TNF IL4 IL2 IL10 IFNG
5 12.38 TNFSF13B TNF IL4 IL2 IL10 IFNG
6
Show member pathways
12.36 IL4 IL2 IL10 IFNG
7
Show member pathways
12.29 TNF IL4 IL2 IFNG
8
Show member pathways
12.22 TNF IL4 IL10 IFNG
9
Show member pathways
12.21 TNF IL4 IL2 IL10 IFNG
10 11.92 TNF IL4 IL2 IL10 IFNG
11 11.84 TNFSF13B TNF IFNG CTLA4
12 11.75 IL4 IL2 IFNG
13
Show member pathways
11.74 CHRNG CHRNE CHRNA1
14
Show member pathways
11.74 TNF IL2 IL10 IFNG
15 11.72 TNF IL2 IL10 IFNG
16 11.67 TNF IL4 IL2 IL10 IFNG
17
Show member pathways
11.63 TNF IL2 IFNG
18
Show member pathways
11.61 TNF IL2 IFNG
19 11.57 RAPSN MUSK CHRNA1 AGRN
20
Show member pathways
11.54 TNF IL4 IL2 IFNG CTLA4
21 11.52 TNF IL2 IFNG
22 11.51 TNFSF13B TNF MBP IL4 IL2 IFNG
23 11.5 TNF IL10 IFNG
24 11.49 TNF IL4 IL10
25 11.47 TNF IL2 IFNG
26 11.44 IL4 IL2 IL10 IFNG
27 11.37 TNFSF13B TNF IL4 IL10 CTLA4
28 11.34 TNF IL10 IFNG
29
Show member pathways
11.29 TNF IL2 IL10 IFNG
30 11.28 IL4 IL2 IFNG
31 11.26 TNF IL4 IFNG
32 11.12 IL4 IL2 IL10 IFNG
33 10.97 TNFSF13B TNF MUSK IL4 IL2 IL10
34 10.78 RYR1 CHRNE CHRNA1
35 10.48 TNF IL4 IL2 IL10 IFNG

GO Terms for Myasthenia Gravis

Cellular components related to Myasthenia Gravis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.1 TTN TNFSF13B TNF RYR1 RAPSN MUSK
2 extracellular region GO:0005576 10.02 TTN TNFSF13B TNF IL4 IL2 IL10
3 cell junction GO:0030054 9.87 RAPSN MUSK CHRNG CHRNE CHRNA1 AGRN
4 synapse GO:0045202 9.56 RAPSN MUSK MBP CHRNG CHRNE CHRNA1
5 postsynaptic membrane GO:0045211 9.55 RAPSN MUSK CHRNG CHRNE CHRNA1
6 neuromuscular junction GO:0031594 9.02 RAPSN MUSK CHRNE CHRNA1 ACHE

Biological processes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.07 TTN TNF MUSK IL4 IFNG
2 positive regulation of protein phosphorylation GO:0001934 9.94 TNF MUSK IL2 IFNG
3 positive regulation of interleukin-6 production GO:0032755 9.85 TNF MBP IFNG
4 chemical synaptic transmission GO:0007268 9.83 RAPSN MBP CHRNG CHRNE CHRNA1
5 positive regulation of T cell proliferation GO:0042102 9.82 TNFSF13B IL4 IL2
6 excitatory postsynaptic potential GO:0060079 9.81 CHRNG CHRNE CHRNA1
7 humoral immune response GO:0006959 9.8 TNF IFNG AIRE
8 positive regulation of cytokine production GO:0001819 9.8 TNF IL10 IFNG
9 nervous system process GO:0050877 9.78 CHRNG CHRNE CHRNA1
10 regulation of postsynaptic membrane potential GO:0060078 9.77 CHRNG CHRNE CHRNA1
11 muscle contraction GO:0006936 9.76 TTN RYR1 CHRNG CHRNE
12 positive regulation of B cell proliferation GO:0030890 9.72 TNFSF13B IL4 IL2
13 neuromuscular junction development GO:0007528 9.71 MUSK CHRNA1 AGRN
14 negative regulation of amyloid-beta clearance GO:1900222 9.67 TNF IFNG
15 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.66 MBP IL10
16 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.66 TNF MBP
17 negative regulation of T-helper 17 cell differentiation GO:2000320 9.65 IL4 IL2
18 positive regulation of isotype switching to IgG isotypes GO:0048304 9.65 IL4 IL2
19 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
20 microglial cell activation GO:0001774 9.65 TNF IL4 IFNG
21 positive regulation of mononuclear cell migration GO:0071677 9.62 TNF IL4
22 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 TNF IL4 IL2 IFNG
23 negative regulation of cytokine production involved in immune response GO:0002719 9.61 TNF IL10
24 positive regulation of cellular respiration GO:1901857 9.59 IL4 IFNG
25 neuroinflammatory response GO:0150076 9.58 IL4 IFNG
26 type 2 immune response GO:0042092 9.58 IL4 IL10
27 regulation of synaptic growth at neuromuscular junction GO:0008582 9.57 MUSK AGRN
28 B cell costimulation GO:0031296 9.56 TNFSF13B IL4
29 positive regulation of plasma cell differentiation GO:1900100 9.52 IL2 IL10
30 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 TNF IFNG
31 regulation of isotype switching GO:0045191 9.49 IL4 IL10
32 regulation of regulatory T cell differentiation GO:0045589 9.43 IL2 IFNG CTLA4
33 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 TNF IFNG
34 positive regulation of nitrogen compound metabolic process GO:0051173 9.37 TNF IFNG
35 positive regulation of MHC class II biosynthetic process GO:0045348 9.33 IL4 IL10 IFNG
36 immune response GO:0006955 9.28 TNFSF13B TNF MBP IL4 IL2 IL10
37 synaptic transmission, cholinergic GO:0007271 9.26 RAPSN CHRNG CHRNE CHRNA1

Molecular functions related to Myasthenia Gravis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.67 TTN RYR1 MBP AKAP12
2 ion channel activity GO:0005216 9.62 RYR1 CHRNG CHRNE CHRNA1
3 neurotransmitter receptor activity GO:0030594 9.58 CHRNG CHRNE CHRNA1
4 acetylcholine binding GO:0042166 9.43 CHRNA1 ACHE
5 extracellular ligand-gated ion channel activity GO:0005230 9.43 CHRNG CHRNE CHRNA1
6 acetylcholine-gated cation-selective channel activity GO:0022848 9.33 CHRNG CHRNE CHRNA1
7 acetylcholine receptor activity GO:0015464 9.13 CHRNG CHRNE CHRNA1
8 cytokine activity GO:0005125 9.1 TNFSF13B TNF IL4 IL2 IL10 IFNG

Sources for Myasthenia Gravis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....